Filtered By:
Management: Marketing
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Silk Road Medical Announces $47 Million Financing led by Norwest Venture Partners and Funds Managed by Janus Capital Management LLC
Financing to Support Rapid Growth of TransCarotid Artery Revascularization (TCAR) Procedure
SUNNYVALE, Calif., July 18, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Road Medical, Inc., a company dedicated to alleviating the devastating burden... Devices, Interventional, Radiology, Venture Capital Silk Road Medical, ENROUTE, TransCarotid Artery Revascularization, stroke
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news
Redivus Health Recognized as Finalist in Fierce Innovation Awards: Healthcare
OLATHE, Kan. — Redivus Health announced that the company has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of FierceHealthcare. Redivus Health was recognized as one of three finalists in the Clinical Information Management category.
Redivus Health was selected as a finalist for its innovative, industry-leading product, which improves patient care by providing physicians, nurses and paramedics with actionable, clinical guidance during a critical care event. The Redivus mobile application, combined with a cloud-based platform, deliver...
Source: JEMS Administration and Leadership - August 11, 2017 Category: Emergency Medicine Authors: Revidus Health Tags: Industry News Administration and Leadership Source Type: news
IRRAS Appoints Fredrik Alpsten as Chief Financial Officer and Deputy CEO
Mr. Alpsten will Lead the Development of IRRAS' Global Finance Strategies
STOCKHOLM, Aug. 30, 2017 -- (Healthcare Sales & Marketing Network) -- IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of in... Devices, Neurosurgery, Monitoring, Personnel IRRAS, IRRAflow, stroke, ICP , intracranial bleeding
Source: HSMN NewsFeed - August 30, 2017 Category: Pharmaceuticals Source Type: news
Johnson and Johnson Medical Devices Companies Signals Commitment to Stroke Treatment With the Announcement of New Neurovascular Business
NICE, France, September 7, 2017 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESM... Devices, Neurology, Interventional Johnson & Johnson, CERENOVUS, neurovascular
Source: HSMN NewsFeed - September 7, 2017 Category: Pharmaceuticals Source Type: news
IRRAS Strengthens Executive and Commercial Teams with Appointments of Karl-Matthias Moehlmann and Klemens Fölling
LA JOLLA, Calif., LAICHINGEN, Germany and STOCKHOLM, Sept. 13, 2017 -- (Healthcare Sales & Marketing Network) -- IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications a... Devices, Neurology, Personnel IRRAS, IRRAflow, stroke, intracranial pressure
Source: HSMN NewsFeed - September 13, 2017 Category: Pharmaceuticals Source Type: news
Cheetah Medical raises $12m
Cheetah Medical said today it raised $11.8 million in an expanded Series C funding round as it looks to grow its US footprint.
Financing was provided by existing investors including MVM Life Science Partners, Springfield Investment Management, Fletcher Spaght Ventures, HighCape Partners and Robert Basch Venture Capital, the Newton, Mass.-based company said.
Cheetah Medical provides noninvasive hemodynamic monitoring devices and systems, including its Cheetah Nicom and Starlin SV technologies, which operate around a proprietary algorithm designed to allow physicians to examine a patient’s full hemodynamic profile.
&#...
Source: Mass Device - September 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cheetah Medical Source Type: news
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency (for specialized target groups only)
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient population
Source: Bayer Company News - November 6, 2017 Category: Pharmaceuticals Source Type: news
First Patient Enrolled in U.S. IDE Study To Evaluate the Potential of New Device To Reduce Stroke Risk in Atrial Fibrillation Patients
Biosense Webster, Inc. Launches U.S. Clinical Study to Evaluate the Safety and Efficacy of the WaveCrest® Left Atrial Appendage Occlusion System
IRVINE, Calif., Jan. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical De... Devices, Interventional Cardiology Biosense Webster, Johnson & Johnson, WaveCrest, Left Atrial Appendage Occlusion
Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news
11.12.17: Not intended for U.S. and UK Media
Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery diseaseThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS studymehr ...
Source: Bayer IR Newsfeed: Events - December 10, 2017 Category: Pharmaceuticals Source Type: news
06.11.17: Not intended for U.S. and UK Media
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines AgencyThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack (1) / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient populationmehr ...
Source: Bayer IR Newsfeed: Events - November 5, 2017 Category: Pharmaceuticals Source Type: news
ESO Solutions Predicts Key Hospital Trends to Watch in 2018
Austin, Texas – ESO Solutions, the leading data and software company serving emergency medical services, fire departments, and hospitals, today shared the trends it predicts will have the biggest impact on hospitals in 2018: A greater emphasis on evidence-based approaches to acute conditions; healthcare financing changes affecting the way hospitals admit and readmit patients; reshuffling of hospital ownership; and a shift in how patient volume is managed.
“Few areas of healthcare have seen more significant change over the past several years than hospitals,” said Allen Johnson, Vice President of ESO HDE and Analytics....
Source: JEMS Patient Care - January 5, 2018 Category: Emergency Medicine Authors: ESO Solutions Tags: Patient Care Industry News Source Type: news
Zynex introduces the NeuroMove(TM) Device to its expanding sales force
LONE TREE, Colo., Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Product Launch Zynex, electrotherapy, NeuroMove
Source: HSMN NewsFeed - February 1, 2018 Category: Pharmaceuticals Source Type: news
Bionik Laboratories Appoints Peter Gerald Malone and Joseph Martin to its Board of Directors
Gains substantial strategic and operational experience within the equity capital markets and the healthcare industry
TORONTO and BOSTON, March 20, 2018 -- (Healthcare Sales & Marketing Network) -- Bionik Laboratories Corp. (OTCQB: BNKL) ("Bionik&q... Devices, Neurology, Personnel Bionik Laboratories, lower extremity rehabilitation, stroke
Source: HSMN NewsFeed - March 20, 2018 Category: Pharmaceuticals Source Type: news
